DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel DiseasesECCO'20 Vienna 2020
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesisECCO'20 Vienna 2020
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control studyECCO'20 Vienna 2020
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort studyECCO'20 Vienna 2020
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)ECCO'20 Vienna 2020
DOP62: Morbidity after primary ileocecal resection for Crohn’s Disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centreECCO'20 Vienna 2020
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trialECCO'20 Vienna 2020
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel DiseasesECCO'20 Vienna 2020
DOP67: CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signaling pathwayECCO'20 Vienna 2020
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centresECCO'20 Vienna 2020
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel DiseaseECCO'20 Vienna 2020